Advanced Breast Cancer Clinical Trials in San Antonio, Texas

8 studies are recruiting for advanced breast cancer in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

   This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Next Oncology, San Antonio, Texas

   Locations

   62 in total

   Run by

   BeOne Medicines

   See if you can join NCT06120283 on ClinicalTrials.gov

2. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

   First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas San Antonio (UTSA), San Antonio, Texas

   Locations

   44 in total

   Run by

   TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

   See if you can join NCT06625775 on ClinicalTrials.gov

3. Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

   The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, San Antonio, Texas

   Locations

   306 in total

   Run by

   AstraZeneca

   See if you can join NCT06380751 on ClinicalTrials.gov

4. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

   This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START San Antonio, LLC, San Antonio, Texas

   Locations

   45 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT06638307 on ClinicalTrials.gov

5. A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

   The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START San Antonio, San Antonio, Texas

   Locations

   13 in total

   Run by

   Pfizer

   See if you can join NCT07318805 on ClinicalTrials.gov

6. Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

   This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT San Antonio, San Antonio, Texas

   Locations

   5 in total

   Run by

   Regor Pharmaceuticals Inc.

   See if you can join NCT07524322 on ClinicalTrials.gov

7. A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

   The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   21 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06997029 on ClinicalTrials.gov

8. Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

   Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START, San Antonio, Texas

   Locations

   15 in total

   Run by

   Ensem Therapeutics

   See if you can join NCT06993844 on ClinicalTrials.gov